• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ENDOLOGIX, INC. ENDOLOGIX; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ENDOLOGIX, INC. ENDOLOGIX; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Model Number BEA22-40/I13-40
Health Effect - Clinical Code Death (1802)
Date of Event 09/15/2020
Type of Reportable Event Death
Event or Problem Description
Patient undergoing endovascular aaa repair.Endograft was twisted upon deployment.Case was converted to open aaa repair.Fda safety report id# (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ENDOLOGIX
Common Device Name
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
ENDOLOGIX, INC.
MDR Report Key10586007
Report NumberMW5096848
Device Sequence Number372633
Product Code MIH
UDI-Device Identifier00818009015075
UDI-Public00818009015075
Initial Reporter StateNY
Initial Reporter CountryUS
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2020
Device Explanted Year2020
Reporter Type Voluntary
Initial Reporter Occupation Nurse
Type of Report Initial
Report Date (Section B) 09/23/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date02/11/2023
Device Model NumberBEA22-40/I13-40
Device Catalogue NumberBEA22-40/I13-40
Was Device Available for Evaluation? No
Initial Date Received by Manufacturer Not provided
Initial Report FDA Received Date09/24/2020
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
Yes
Patient Sequence Number1
Outcome Attributed to Adverse Event Death; Life Threatening;
Patient Age56 YR
Patient Weight86
-
-